Screener
Eikon Therapeutics, Inc. EIKN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Eikon Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216791
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(82,958) | $(68,243) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 5,214 | 3,789 |
| Stock-based compensation expense | 2,777 | 2,970 |
| Amortization of operating lease right-of-use assets | (101) | 2,677 |
| Amortization of premiums and accretion of discounts on marketable securities | (827) | (1,234) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,377) | (2,686) |
Item 1. Condensed Financial Statements (Unaudited).
FAQ
- What is Eikon Therapeutics, Inc.'s stock-based comp?
- Eikon Therapeutics, Inc. (EIKN) reported stock-based comp of $2.78M in Q1 2026.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Eikon Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude